Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €31.86 EUR
Change Today +0.92 / 2.97%
Volume 0.0
HO1 On Other Exchanges
Symbol
Exchange
Berlin
As of 3:44 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

hologic inc (HO1) Snapshot

Open
€31.07
Previous Close
€30.94
Day High
€31.89
Day Low
€30.74
52 Week High
05/22/15 - €31.89
52 Week Low
05/27/14 - €17.11
Market Cap
9.0B
Average Volume 10 Days
10.0
EPS TTM
--
Shares Outstanding
281.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HOLOGIC INC (HO1)

hologic inc (HO1) Related Businessweek News

No Related Businessweek News Found

hologic inc (HO1) Details

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States and internationally. The company operates in four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment provides Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, instrumentation, Invader chemistry platform, ThinPrep system, fetal fibronectin tests, Procleix family of assays, and virology and infectious disease products. The Breast Health segment provides breast imaging and related products and accessories, including digital and film-based mammography systems; computer-aided detection (CAD) for mammography; invasive breast biopsy devices; breast biopsy site markers; breast biopsy guidance systems; and breast brachytherapy products. This segment also offers Dimensions platform, a mammography gantry for 2D and 3D image acquisition and display; C-View that provides a 2D image; breast MRI coils and workstations; and photoconductor coatings. The GYN Surgical segment provides NovaSure system to treat women suffering from abnormal uterine bleeding; and MyoSure system for the hysteroscopic removal of fibroids. The Skeletal Health segment offers discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient’s extremities, such as the hand, wrist, knee, foot, and ankle. Hologic, Inc. sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. The company has a strategic alliance with Quest Diagnostics Incorporated. Hologic, Inc. was founded in 1985 and is headquartered in Bedford, Massachusetts.

5,351 Employees
Last Reported Date: 11/20/14
Founded in 1985

hologic inc (HO1) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $792.3K
Chief Financial Officer
Total Annual Compensation: $147.1K
Chief Operating Officer
Total Annual Compensation: $199.0K
Executive Officer
Total Annual Compensation: $600.0K
Compensation as of Fiscal Year 2014.

hologic inc (HO1) Key Developments

Hologic Inc. Announces Net Debt for the First Half of Fiscal Year 2015

Hologic Inc. announced net debt for the first half of fiscal year 2015. The company have about $3.3 billion of net debt on the balance sheet as of midyear.

Hologic Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 01:40 PM

Hologic Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 01:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Stephen P. MacMillan, Chief Executive Officer, President and Director.

Hologic Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 28, 2015; Provides Earnings Guidance for the Third Quarter of Fiscal 2015; Revises Earnings Guidance for the Full Year of Fiscal 2015

Hologic Inc. announced unaudited consolidated earnings results for the second quarter and six months ended March 28, 2015. For the quarter, the company reported total revenues of $655.5 million compared to $625 million a year ago. Income from operations was $109.8 million compared to $50.2 million a year ago. Income before income taxes was $60.8 million compared to loss before income taxes of $11.8 million a year ago. Net income was $47.8 million or $0.17 per basic and diluted share compared to net loss of $16.8 million or $0.06 per basic and diluted share a year ago. Non-GAAP income from operations was $219.6 million compared to $202.6 million a year ago. Non-GAAP pre-tax income was $179.5 million compared to $157.4 million a year ago. Non-GAAP net income was $118.9 million compared to $103.1 million a year ago. Non-GAAP diluted earnings per share were $0.41 compared to $0.37 a year ago. Adjusted EBITDA was $238.6 million compared to $222.4 million a year ago. Total debt outstanding at the end of the second fiscal quarter was $3,939.8 million, a $327.9 million decrease from the end of fiscal 2014. Operating cash flow was $157.8 million, while free cash flow, defined as operating cash flow less capital expenditures, was $139.2 million. For the six months, the company reported total revenues of $1,308.3 million compared to $1,237.4 million a year ago. Income from operations was $213.3 million compared to $111.5 million a year ago. Income before income taxes was $104.9 million compared to loss before income taxes of $13.2 million a year ago. Net income was $77.0 million or $0.27 per diluted share compared to net loss of $22.1 million or $0.08 per diluted share a year ago. Net cash provided by operating activities was $311.3 million compared to $218.3 million a year ago. Purchase of property and equipment was $20 million compared to $19.8 million a year ago. Increase in equipment under customer usage agreements was $19.7 million compared to $18 million a year ago. Increase in other assets was $0.6 million compared to $1.9 million a year ago. Non-GAAP income from operations was $434.5 million compared to $393.9 million a year ago. Non-GAAP pre-tax income was $350.7 million compared to $301.1 million a year ago. Non-GAAP net income was $230.6 million compared to $197.3 million a year ago. Non-GAAP diluted earnings per share were $0.81 compared to $0.71 a year ago. Adjusted EBITDA was $471.7 million compared to $435.9 million a year ago. Based on its strong performance in the second quarter of fiscal 2015, the company is raising its full year 2015 revenue and non-GAAP EPS guidance. The guidance for reported results is based on recent foreign exchange rates. Percentage changes from the prior year exclude the one-time benefit associated with amending the Roka license agreement, which added $20.1 million of revenue and $0.05 of EPS to the fourth quarter of fiscal 2014. For the full year of 2015, the company expects revenues to be in the range from $2,600 million to $2,620 million and non-GAAP EPS to be in the range from $1.57 to $1.59 against previously expected revenues to be in the range from $2,570 million to $2,600 million and non-GAAP EPS to be in the range from $1.54 to $1.57. This translates to reported EPS growth between 7.5% and 8.9% or 11.6% to 13% on a constant-currency basis. Increased EPS guidance incorporates some incremental investments both to accelerate and extend growth prospects, especially in Breast Health and Diagnostics. It assumes a slightly lower tax rate of 34.25% for the full year, but a higher diluted share count of 289 million for the year due mainly to a higher share price making some of convertible notes in the money. For the third quarter of fiscal 2015, the company expects revenues to be in the range from $645 million to $655 million and non-GAAP EPS to be in the range from $0.38 to $0.39. This guidance reflects reported revenue growth of 2% to 3.5% and constant currency growth of 4.7% to 6.3%. So despite the fact that comps are getting tougher, the company is still projecting solid mid-single-digit growth on the top line for the third quarter. Non-GAAP EPS is expected to grow 2.7% to 5.4% on a reported basis or roughly 8.1% to 10.8% on a constant-currency basis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HO1:GR €31.86 EUR +0.92

HO1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DENTSPLY International Inc $51.86 USD -0.51
MEDNAX Inc $71.37 USD +0.28
Mettler-Toledo International Inc $330.59 USD -0.25
ResMed Inc $57.08 USD -0.24
Cooper Cos Inc/The $180.75 USD +0.95
View Industry Companies
 

Industry Analysis

HO1

Industry Average

Valuation HO1 Industry Range
Price/Earnings 85.4x
Price/Sales 3.8x
Price/Book 4.5x
Price/Cash Flow 18.1x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOLOGIC INC, please visit www.hologic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.